Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,001 to 1,020 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation. | Nucleic Acids Res | 2022 | 36300627 | PubTator, text mining | PubMed |
| Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma. | J Investig Med High Impact Case Rep | 2022 | 36300378 | PubTator, text mining | PubMed |
| Ubiquitin Proteasome Gene Signatures in Ependymoma Molecular Subtypes. | Int J Mol Sci | 2022 | 36293188 | PubTator, text mining | PubMed |
| NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial. | Cancers (Basel) | 2022 | 36291952 | PubTator, text mining | PubMed |
| Cereblon Deficiency Contributes to the Development of Elastase-Induced Emphysema by Enhancing NF-κB Activation. | Antioxidants (Basel) | 2022 | 36290703 | PubTator, text mining | PubMed |
| Activity of a Novel Anti-Inflammatory Agent F-3,6'-dithiopomalidomide as a Treatment for Traumatic Brain Injury. | Biomedicines | 2022 | 36289711 | PubTator, text mining | PubMed |
| Applications of covalent chemistry in targeted protein degradation. | Chem Soc Rev | 2022 | 36285735 | PubTator, text mining | PubMed |
| Bioengineered Pancreas-Liver Crosstalk in a Microfluidic Coculture Chip Identifies Human Metabolic Response Signatures in Prediabetic Hyperglycemia. | Adv Sci (Weinh) | 2022 | 36285680 | PubTator, text mining | PubMed |
| Targeting the ubiquitin system by fragment-based drug discovery. | Front Mol Biosci | 2022 | 36275626 | PubTator, text mining | PubMed |
| Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation. | ACS Pharmacol Transl Sci | 2022 | 36268122 | PubTator, text mining | PubMed |
| Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary. | Pathol Oncol Res | 2022 | 36262875 | PubTator, text mining | PubMed |
| The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron. | Nature | 2022 | 36261529 | PubTator, text mining | PubMed |
| Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component. | Comput Biol Chem | 2022 | 36252444 | PubTator, text mining | PubMed |
| Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin. | Mol Ther Nucleic Acids | 2022 | 36250201 | PubTator, text mining | PubMed |
| Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents. | Molecules | 2022 | 36235168 | PubTator, text mining | PubMed |
| Discovery of E3 Ligase Ligands for Target Protein Degradation. | Molecules | 2022 | 36235052 | PubTator, text mining | PubMed |
| Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study. | J Clin Med | 2022 | 36233774 | PubTator, text mining | PubMed |
| MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment. | Int J Mol Sci | 2022 | 36232374 | PubTator, text mining | PubMed |
| Allosteric Antagonism of the Pregnane X Receptor (PXR): Current-State-of-the-Art and Prediction of Novel Allosteric Sites. | Cells | 2022 | 36230936 | PubTator, text mining | PubMed |
| Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1. | Eur J Med Chem | 2022 | 36228414 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=51